Area of research
Epidemiology · Infectious Diseases
Research interest
Research interests include Respiratory viral infections research, HIV Research and Treatment, Viral gastroenteritis research and epidemiology, and SARS-CoV-2 and COVID-19 Research.
Efficacious human metapneumovirus vaccine based on AI-guided engineering of a closed prefusion trimer.
A foldon-free prefusion F trimer vaccine for respiratory syncytial virus to reduce off-target immune responses.
Universal paramyxovirus vaccine design by stabilizing regions involved in structural transformation of the fusion protein.
Absolute quantitation of binding antibodies from clinical samples.
Structural basis for potent neutralization of human respirovirus type 3 by protective single-domain camelid antibodies.
Engineering a cleaved, prefusion-stabilized influenza B virus hemagglutinin by identification and locking of all six pH switches.
Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models.
Convergence of immune escape strategies highlights plasticity of SARS-CoV-2 spike.
Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen.
Universal stabilization of the influenza hemagglutinin by structure-based redesign of the pH switch regions.
Combination Ad26.RSV.preF/RSV preF protein vaccine induces superior humoral, cellular, and protective immunity compared with individual vaccine components in preclinical models
Stabilizing the closed SARS-CoV-2 spike trimer.
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease.
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study
Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers.
Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition
Structural Rearrangements of the Central Region of the Morbillivirus Attachment Protein Stalk Domain Trigger F Protein Refolding for Membrane Fusion
Epitope Mapping of Broadly Neutralizing HIV-2 Human Monoclonal Antibodies